Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$14.36 USD
-1.03 (-6.69%)
Updated May 3, 2024 04:00 PM ET
After-Market: $14.00 -0.36 (-2.51%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AVTX 14.36 -1.03(-6.69%)
Will AVTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AVTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVTX
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
AVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
New Strong Buy Stocks for January 3rd
Other News for AVTX
Oppenheimer Predicts Over 100% Rally for These 2 Healthcare Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
Oppenheimer more bullish on Avalo Therapeutics, upgrades to Outperform
Oppenheimer gets more bullish on Avalo Therapeutics, upgrades shares
12 Health Care Stocks Moving In Tuesday's After-Market Session